EFFICACY AND SAFETY OF QUIZARTINIB (AC220) IN PATIENTS AGE ≥60 YEARS WITH FLT3-ITD-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

被引：0
|
作者：
Doehner, H. [1 ]
Perl, A. [2 ]
Rousselot, P. [3 ]
Marie, J. [4 ,5 ]
Martinelli, G. [6 ]
Gammon, G. [7 ]
Trone, D. [7 ]
Cortes, J. [8 ]
Levis, M. [9 ]
机构：
[1] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[2] Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA
[3] Univ Versailles St Quentin Yvelines, Hop Versailles, Serv Hematol & Oncol, Le Chesnay, France
[4] Hop St Antoine, AP HP, Dept Hematol, Paris, France
[5] Univ Paris, Paris, France
[6] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
[7] Ambit Biosci Corp, San Diego, CA USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[9] Johns Hopkins Univ, Sch Med, Dept Oncol, Div Hematol Malignancies, Baltimore, MD 21205 USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S558
引用
收藏
页码：233 / 233
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).
    Perl, Alexander E.
    Dohner, Hartmut
    Rousselot, Philippe H.
    Marie, Jean-Pierre
    Martinelli, Giovanni
    Shah, Neil P.
    Levis, Mark J.
    Gammon, Guy
    Trone, Denise
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] HIGH RESPONSE RATE AND BRIDGING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH QUIZARTINIB (AC220) IN PATIENTS WITH FLT3-ITD-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    Levis, M.
    Cortes, J.
    Perl, A.
    Doehner, H.
    Steffens, B.
    Rousselot, P.
    Martinelli, G.
    Estey, E.
    Burnett, A.
    Gammon, G.
    Trone, D.
    Dombret, H.
    HAEMATOLOGICA, 2013, 98 : 17 - 17
  • [3] Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia
    Cortes, Jorge E.
    Perl, Alexander E.
    Dombret, Herve
    Kayser, Sabine
    Steffen, Bjoern
    Rousselot, Philippe
    Martinelli, Giovanni
    Estey, Elihu H.
    Burnett, Alan K.
    Gammon, Guy
    Trone, Denise
    Leo, Eugen
    Levis, Mark J.
    BLOOD, 2012, 120 (21)
  • [4] TREATMENT WITH QUIZARTINIB (AC220) ENABLES A HIGH RATE OF PATIENTS WITH RELAPSED OR REFRACTORY FLT3-ITD(+) ACUTE MYELOID LEUKEMIA TO BE BRIDGED TO HSCT
    Martinelli, G.
    Levis, M. J.
    Perl, A. E.
    Dombret, H.
    Steffen, B.
    Rousselot, P.
    Estey, E. H.
    Shah, N. P.
    Gammon, G.
    Trone, D.
    Cortes, J. E.
    HAEMATOLOGICA, 2014, 99 : 35 - 35
  • [5] QUIZARTINIB (AC220) IN PATIENTS WITH FLT3-ITD(+) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A RANDOMIZED PHASE 2 STUDY
    Russell, N.
    Tallman, M. S.
    Goldberg, S.
    Perl, A. E.
    Marie, J. P.
    Martinelli, G.
    Larson, R. A.
    Schiller, G.
    Trone, D.
    Gammon, G.
    Levis, M.
    Cortes, J. E.
    HAEMATOLOGICA, 2014, 99 : 36 - 36
  • [6] Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
    Fletcher, Luke
    Joshi, Sunil K.
    Traer, Elie
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 151 - 163
  • [7] Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-Itd- Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Levis, Mark J.
    Cortes, Jorge E.
    Gammon, Guy M.
    Trone, Denise
    Kang, Dongwoo
    Li, Jianke
    BLOOD, 2016, 128 (22)
  • [8] Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.
    Schiller, Gary J.
    Tallman, Martin S.
    Goldberg, Stuart L.
    Perl, Alexander E.
    Marie, Jean-Pierre
    Martinelli, Giovanni
    Larson, Richard A.
    Russell, Nigel
    Trone, Denise
    Gammon, Guy
    Levis, Mark J.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.
    Martinelli, Giovanni
    Perl, Alexander E.
    Dombret, Herve
    Kayser, Sabine
    Steffen, Bjoern
    Rousselot, Philippe H.
    Estey, Elihu
    Burnett, Alan K.
    Shah, Neil P.
    Gammon, Guy
    Trone, Denise
    Levis, Mark J.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)
    Cortes, Jorge E.
    Tallman, Martin S.
    Schiller, Gary
    Trone, Denise
    Gammon, Guy
    Goldberg, Stuart
    Perl, Alexander E.
    Marie, Jean Pierre
    Martinelli, Giovanni
    Levis, Mark
    BLOOD, 2013, 122 (21)
12345